Novo Nordisk achieved strong results in sales of Wegovy obesity pills, with sales significantly exceeding analysts' expectations during the first quarter of the year, while the company confirmed its readiness to expand the drug's availability to new markets outside the United States in the coming periods.
Grain sales significantly exceeded expectations.
Wegovy cereals performed strongly during the first three months of the year, with sales reaching approximately 2.3 billion Danish kroner, while analysts' expectations were only around half that figure.
DR explained that this strong performance directly contributed to the significant rise in Novo Nordisk's stock after the quarterly results were announced, as the company has already issued more than one million prescriptions for the pills within the United States since its launch there. This means that sales came in almost twice as high as market expectations, which investors considered a strong indicator of the growing demand for obesity treatment drugs.
The company is preparing to launch the grains in new markets.
Novo Nordisk's Chief Financial Officer, Karsten Munk Knudsen, also confirmed that the company is preparing to launch Wegovy beans in new markets outside the United States in the coming period.
He explained during a conference call that the company has high expectations for the drug in the next phase, but he declined to reveal the names of the new markets that the company is preparing to enter, justifying this with considerations related to competition, according to what was reported by MarketWire.
Widespread interest in the new obesity treatment
Novo Nordisk CEO Mike Doustdar expressed his satisfaction with the results of the new pill launch, confirming that the company has seen widespread interest in the treatment since its introduction to the US market.
وقال خلال مؤتمر هاتفي إن إطلاق ويغوفي Wegovy يعد أفضل إطلاق لدواء جديد – باستثناء اللقاحات – خلال سنوات عديدة.
He added that the company continues to record increasing growth even with the entry of new competitors into the obesity drug market, including Eli Lilly, which has introduced a similar treatment.
Mike Dodestar explained, according to MarketWire, that the company has not yet seen any signs of patients stopping treatment at an early stage, noting that the current data only covers the first 16 weeks of use, but he confirmed that the indicators are developing positively week after week.
-
-
-
-
